Proteomic signatures in antibiotic research

Proteomics

Volumn 11, Issue 15, 2011, Pages 3256-3268

  Wenzel, Michaela ^a   Bandow, Julia E ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antibiotics; Drug mechanism of action; Microbiology; Proteomic signature

Indexed keywords

ANTIBIOTIC AGENT;

AUTORADIOGRAPHY; BACILLUS SUBTILIS; BACTERIUM; DRUG INHIBITION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HYPOTHESIS; IN VIVO STUDY; INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL PROTEINS; PROTEOMICS;

BACTERIA (MICROORGANISMS);

EID: 79960399946     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100046     Document Type: Review

References (93)

1. Waksman, S. A., What is an antibiotic or an antibiotic substance? Mycologia 1947, 39, 565-569.
2. Aminov, R. I., The role of antibiotics and antibiotic resistance in nature. Environ. Microbiol. 2009, 11, 2970-2988.
3. Hazlett, L., Wu, M., Defensins in innate immunity. Cell Tissue Res. 2011, 343, 175-188.
4. Salmi, C., Loncle, C., Vidal, N., Letourneux, Y. et al., Squalamine: an appropriate strategy against the emergence of multidrug resistant Gram-negative bacteria? PLoS One 2008, 3, e2765.
5. Aiello, A. E., Larson, E. L., Sedlak, R., The health revolution: medical and socioeconomic advances. Am. J. Infect. Control 2008, 36, 116-127.
6. Centers for Disease Control and Prevention (CDC). Control of infectious diseases. MMWR Morb. Mortal. Wkly. Rep. 1999, 48, 621-629.
7. Ehrlich, P., Bertheim, A., Über das salzsaure 3.3'-diamino-4.4'-dioxy-arsenobenzol und seine nächsten Verwandten. Berichte der Deutschen Chemischen Gesellschaft 1912, 45, 756-766.
8. Domagk, G., Beitrag zur Chemotherapie der bakteriellen Infektionen. Deutsche Medizinische Wochenschrift 1935, 61, 250-253.
9. Sassetti, C. M., Rubin, E. J., The open book of infectious diseases. Nat. Med. 2007, 13, 279-280.
10. Aminov, R. I., Mackie, R. I., Evolution and ecology of antibiotic resistance genes. FEMS Microbiol. Lett. 2007, 271, 147-161.
11. Kirby, W. M., Rantz, L. A., Sulfonamide resistance. Cal. West. Med. 1942, 57, 174-175.
12. Barlow, M., What antimicrobial resistance has taught us about horizontal gene transfer. Methods Mol. Biol. 2009, 532, 397-411.
13. Abraham, E. P., Chain, E., An enzyme from bacteria able to destroy penicillin. Nature 1940, 146, 837.
14. Abraham, E. P., Chain, E., Fletcher, C. M., Gardner, A. D. et al., Further observations on penicillin. Lancet 1941, 2, 177-189.
15. Fleming, A., Penicillin. Nobel Lecture, December 11, 1945. In: From Nobel Lectures, Physiology or Medicine 1942-1962, Elsevier Publishing Company, Amsterdam 1964, pp. 83-93.
16. Kloss, P., Xiong, L., Shinabarger, D. L., Mankin, A. S., Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. 1999, 294, 93-101.
17. Bush, K., Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 2004, 10, 10-17.
18. Goossens, H., Ferech, M., Vander Stichele, R., Elseviers, M., ESAC Project Group., Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365, 579-587.
19. Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S. et al., Active Bacterial Core surveillance (ABCs) MRSA investigators, invasive methicillin-resistant Staphylococcus aureus infections in the United States. J. Am. Med. Assoc. 2007, 298, 1763-1771.
20. Stryjewski, M. E., Chambers, H. F., Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46, 368-377.
21. ECDC/EMEA Joint Working Group. The Bacterial Challenge, The Publications Office of the European Union, Stockholm 2009.
22. Rolinson, G. N., Forty years of beta-lactam research. J. Antimicrob. Chemother. 1998, 41, 589-603.
23. Pichichero, M. E., Cephalosporins can be prescribed safely for penicillin-allergic patients. J. Fam. Pract. 2006, 55, 106-112.
24. Ball, P., The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections. Int. J. Antimicrob. Agents 2007, 30, 113-117.
25. Talbot, G. H., Bradley, J., Edwards Jr., J. E., Gilbert, D. et al., Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42, 657-668.
26. Shama, G., Chapter 5: zones of inhibition? The transfer of information relating to penicillin in Europe during World War II. Adv. Appl. Microbiol. 2009, 69, 133-158.
27. Bush, K., Why it is important to continue antibacterial drug discovery. ASM News 2004, 70, 282-287.
28. Stubbings, W., Labischinski, H., New antibiotics for antibiotic-resistant bacteria. F1000 Biol. Rep. 2009, 1, 40-43.
29. Brötz-Oesterhelt, H., Sass, P., Postgenomic strategies in antibacterial drug discovery. Fut. Microbiol. 2010, 5, 1553-1579.
30. Souli, M., Galani, I., Giamarellou, H., Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro. Surveill. 2008, 13, pii:19045.
31. Council of the European Union, Council Conclusions on Innovative Incentives for Effective Antibiotics, 2980th Employment, Social Policy, Health and Consumer Affairs Council Meeting, Brussels 2009.
32. Infectious Diseases Society of America. The 10×'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010, 50, 1081-1083.
33. Lederberg, J., Mechanism of action of penicillin. J. Bacteriol. 1957, 73, 144.
34. Guay, D. R., An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001, 61, 353-364.
35. Bandow, J. E., Brötz, H., Leichert, L. I., Labischinski, H., Hecker, M., Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother. 2003, 47, 948-955.
36. Schneider, T., Kruse, T., Wimmer, R., Wiedemann, I. et al., Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010, 328, 1168-1172.
37. Brötz-Oesterhelt, H., Beyer, D., Kroll, H. P., Endermann, R. et al., Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 2005, 11, 1082-1087.
38. Brötz-Oesterhelt, H., Brunner, N. A., How many modes of action should an antibiotic have? Curr. Opin. Pharmacol. 2008, 8, 564-573.
39. Rosamond, J., Allsop, A., Harnessing the power of the genome in the search for new antibiotics. Science 2000, 287, 1973-1976.
40. Mills, S. D., The role of genomics in antimicrobial discovery. J. Antimicrob. Chemother. 2003, 51, 749-752.
41. Freiberg, C., Brotz-Oesterhelt, H., Functional genomics in antibacterial drug discovery. Drug Discov. Today 2005, 1, 927-935.
42. Nicola, G., Abagyan, R., Structure-based approaches to antibiotic drug discovery. Curr. Protoc. Microbiol. 2009, Chapter 17: Unit 17.2.
43. O'Shea, R., Moser, H. E., Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 2008, 51, 2871-2878.
44. Bandow, J. E., Proteomic approaches to antibiotic drug discovery. Curr. Protoc. Microbiol. 2005, Chapter 1: Unit 1F.2.
45. Hecker, M., Antelmann, H., Büttner, K., Bernhardt, J., Gel-based proteomics of Gram-positive bacteria: a powerful tool to address physiological questions. Proteomics 2008, 8, 4958-4975.
46. Neidhardt, F. C., Ingraham, J. L., Schaechter, M., Physiology of the Bacterial Cell: A Molecular Approach, Sinauer Associates, Sunderland, MA 1990, pp. 351-388.
47. VanBogelen, R. A., Schiller, E., Thomas, J. D., Neidhardt, F. C., Diagnosis of cellular states of microbial organisms using proteomics. Electrophoresis 1999, 20, 2149-2159.
48. Kirillov, S., Porse, B. T., Vester, B., Woolley, P., Garrett, R. A., Movement of the 3'-end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. FEBS Lett. 1997, 406, 223-233.
49. Beyer, D., Kroll, H. P., Endermann, R., Schiffer, G. et al., New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob. Agents Chemother. 2004, 48, 525-532.
50. Wang, J., Soisson, S. M., Young, K., Shoop, W. et al., Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441, 358-361.
51. Wang, J., Kodali, S., Lee, S. H., Galgoci, A. et al., Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci. USA 2007, 104, 7612-7616.
52. Wright, H. T., Reynolds, K. A., Antibacterial targets in fatty acid biosynthesis. Curr. Opin. Microbiol. 2007, 10, 447-453.
53. Heath, R. J., Rock, C. O., Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs 2004, 5, 146-153.
54. Barykina, O. V., Rossi, K. L., Rybak, M. J., Snider, B. B., Synthesis and antibacterial properties of (-)-nor-platencin. Org. Lett. 2009, 11, 5334-5337.
55. Jang, K. P., Kim, C. H., Na, S. W., Jang, D. S. et al., 7-Phenylplatensimycin and 11-methyl-7-phenylplatensimycin: more potent analogs of platensimycin. Bioorg. Med. Chem. Lett. 2010, 20, 2156-2158.
56. Nicolaou, K. C., Tria, G. S., Edmonds, D. J., Kar, M., Total syntheses of (+/-)-platencin and (-)-platencin. J. Am. Chem. Soc. 2009, 131, 15909-15917.
57. Patra, M., Gasser, G., Wenzel, M., Merz, K. et al., Synthesis and biological evaluation of ferrocene-containing bioorganometallics inspired by the platensimycin lead structure. Organometallics 2010, 29, 4312-4319.
58. Shen, H. C., Ding, F. X., Singh, S. B., Parthasarathy, G. et al., Synthesis and biological evaluation of platensimycin analogs. Bioorg. Med. Chem. Lett. 2009, 19, 1623-1627.
59. Tiefenbacher, K., Gollner, A., Mulzer, J., Syntheses and antibacterial properties of iso-platencin, Cl-iso-platencin and Cl-platencin: identification of a new lead structure. Chemistry 2010, 16, 9616-9622.
60. Waalboer, D. C., Leenders, S. H., Schülin-Casonato, T., van Delft, F. L., Rutjes, F. P., Total synthesis and antibiotic activity of dehydrohomoplatencin. Chemistry 2010, 16, 11233-11236.
61. Yeung, Y. Y., Corey, E. J., A simple, efficient, and enantiocontrolled synthesis of a near-structural mimic of platensimycin. Org. Lett. 2008, 10, 3877-3878.
62. Herath, K. B., Zhang, C., Jayasuriya, H., Ondeyka, J. G. et al., Structure and semisynthesis of platensimide A, produced by Streptomyces platensis. Org. Lett. 2008, 10, 1699-1702.
63. Zhang, C., Ondeyka, J., Dietrich, L., Gailliot, F. P. et al., Isolation, structure and biological activities of platencin A(2)-A(4) from Streptomyces platensis. Bioorg. Med. Chem. 2010, 18, 2602-2610.
64. Wenzel, M., Patra, M., Albrecht, D., Chen, D. Y.-K. et al., Proteomic signature of fatty acid biosynthesis inhibition available for in vivo mechanism of action studies. Antimicrob. Agents Chemother, 2011, 55, 2590-2596.
65. Patra, M., Gasser, G., Pinto, A., Merz, K. et al., Synthesis and biological evaluation of chromium bioorganometallics based on the antibiotic platensimycin lead structure. Chem. Med. Chem. 2009, 4, 1930-1938.
66. Lee, B. G., Park, E. Y., Lee, K. E., Jeon, H. et al., Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. Nat. Struct. Mol. Biol. 2010, 17, 471-478.
67. Kirstein, J., Hoffmann, A., Lilie, H., Schmidt, R. et al., The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol. Med. 2009, 1, 37-49.
68. Böttcher, T., Sieber, S. A., Beta-lactones as specific inhibitors of ClpP attenuate the production of extracellular virulence factors of Staphylococcus aureus. J. Am. Chem. Soc. 2008, 130, 14400-14401.
69. Higgins, P. G., Fluit, A. C., Schmitz, F. J., Fluoroquinolones: structure and target sites. Curr. Drug Targets 2003, 4, 181-190.
70. Apfel, C. M., Locher, H., Evers, S., Takacs, B. et al., Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 2001, 45, 1058-1064.
71. Haas, M., Beyer, D., Gahlmann, R., Freiberg, C., YkrB is the main peptide deformylase in Bacillus subtilis, a eubacterium containing two functional peptide deformylases. Microbiology 2001, 147, 1783-1791.
72. Bandow, J. E., Becher, D., Büttner, K., Hochgräfe, F. et al., The role of peptide deformylase in protein biosynthesis: a proteomic study. Proteomics 2003, 3, 299-306.
73. Wecke, T., Zühlke, D., Mäder, U., Jordan, S. et al., Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses. Antimicrob. Agents Chemother. 2009, 53, 1619-1623.
74. Muraih, J. K., Pearson, A., Silverman, J., Palmer, M., Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 2011, 1808, 1154-1160.
75. Straus, S. K., Hancock, R. E., Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 2006, 1758, 1215-1223.
76. La Plante, K. L., Rybak, M. J., Daptomycin - a novel antibiotic against Gram-positive pathogens. Exp. Opin. Pharmacother. 2004, 5, 2321-2331.
77. Hahne, H., Mäder, U., Otto, A., Bonn, F. et al., A comprehensive proteomics and transcriptomics analysis of Bacillus subtilis salt stress adaptation. J. Bacteriol. 2010, 192, 870-882.
78. Fränzel, B., Frese, C., Penkova, M., Metzler-Nolte, N. et al., Corynebacterium glutamicum exhibits a membrane-related response to a small ferrocene-conjugated antimicrobial peptide. J. Biol. Inorg. Chem. 2010, 15, 1293-1303.
79. Nanduri, B., Lawrence, M. L., Peddinti, D. S., Burgess, S. C., Effects of subminimum inhibitory concentrations of antibiotics on the Pasteurella multocida proteome: a systems approach. Comp. Funct. Genomics 2008, 254836.
80. Wang, R., Marcotte, E. M., The proteomic response of Mycobacterium smegmatis to anti-tuberculosis drugs suggests targeted pathways. J. Proteome Res. 2008, 7, 855-865.
81. Hughes, M. A., Silva, J. C., Geromanos, S. J., Townsend, C. A., Quantitative proteomic analysis of drug-induced changes in mycobacteria. J. Proteome Res. 2006, 5, 54-63.
82. Freiberg, C., Fisher, H. P., Brunner, N. A., Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants. Antimicrob. Agents Chemother. 2005, 49, 749-759.
83. Brötz-Oesterhelt, H., Bandow, J. E., Labischinski, H., Bacterial proteomics and its role in antibacterial drug discovery. Mass Spectrom. Rev. 2005, 24, 549-565.
84. Freiberg, C., Brotz-Oesterhelt, H., Labischinski, H., The impact of transcriptome and proteome analyses on antibiotic drug discovery. Curr. Opin. Microbiol. 2004, 7, 451-459.
85. Baba, T., Ara, T., Hasegawa, M., Takai, Y. et al., Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2006, 2:2006.0008.
86. Liu, A., Tran, L., Becket, E., Lee, K. et al., Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic barcode. Antimicrob. Agents Chemother. 2010, 54, 1393-1403.
87. Tamae, C., Liu, A., Kim, K., Sitz, D. et al., Determination of antibiotic hypersensitivity among 4, 000 single-gene-knockout mutants of Escherichia coli. J. Bacteriol. 2008, 190, 5981-5988.
88. VanBogelen, R. A., Neidhardt, F. C., Ribosomes as sensors of heat and cold shock in Escherichia coli. Proc. Natl. Acad. Sci. USA 1990, 87, 5589-5593.
89. Argyrou, A., Jin, L., Siconilfi-Baez, L., Angeletti, R. H., Blanchard, J. S., Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 2006, 45, 13947-13953.
90. Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P. et al., Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 2009, 458, 83-86.
91. Balemans, W., Lounis, N., Gilissen, R., Guillemont, J. et al., Essentiality of FASII pathway for Staphylococcus aureus. Nature 2010, 463, E3-E4.
92. Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P. et al., Brinster et al. reply. Nature 2010, 463, E4-E5.
93. Escaich, S., Antivirulence as a new antibacterial approach for chemotherapy. Curr. Opin. Chem. Biol. 2008, 12, 400-408.